Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNM002 vs human tetanus immunoglobulin for passive immunization against tetanus
CTR20223067Phase 3Completed
- Sponsor
- Trinomab Pharmaceutical
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of siltartoxatug in Tetanus, sponsored by Trinomab Pharmaceutical. Started Nov 2022; status: completed.
02
Drugs
siltartoxatug
03
Conditions
Tetanus
Beyond the preview
Go deeper on CTR20223067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223067.